Loxapine succinate 是一种具有口服活性的多巴胺(dopamine) 抑制剂和5-HT受体拮抗剂,有抗精神病活性。Loxapine 还能抑制细菌外排泵的活性,抑制巨噬细胞内多重耐药肠道鼠伤寒沙门氏菌。
生物活性 | Loxapine succinate is an orally activedopamineinhibitor,5-HT receptorantagonist and also a dibenzoxazepine anti-psychotic agent. Loxapine can also suppressesbacterialefflux pump activity and inhibit intracellular multiple-antibiotic-resistantSalmonella entericaserovar Typhimurium in macrophages[1][4][6]. |
IC50& Target | human 5-HT2 | Human D4Receptor | Human D1Receptor | Human D2Receptor |
|
体外研究 (In Vitro) | In the presence of Loxapine, [3H]ketanserin binds to 5-HT2receptor in Frontal cortex of brain in human and bovine with Kivalue of 6.2 nM and 6.6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows: 5-HT2≥D4>>>D1>D2in comparing competition experiments involving the human membranes[1]. Loxapine (0-20 μM, 24 h or 72 h) reduces IL-1β secretion by LPS-activated mixed glia cultures, reduces IL-2 secretion in mixed glia cultures, and decreases IL-1β and IL-2 secretion in LPS-induced microglia cultures[2]. Loxapine (4 μM, 24 h) is active against multiple-antibiotic-resistant or Fluoroquinolone-resistantS. Typhimurium[6]. Loxapine (1, 2, 4 and 8 μM) suppresses intracellularMethicillin-resistantS. aureus(MRSA),Y. enterocoliticaandS. flexneriin RAW264.7[6].
|
体内研究 (In Vivo) | Loxapine (5 mg/kg; i.p.; daily for 4 or 10 weeks) decreases serotonin (S2) but does not elevate dopamine (D2) receptor numbers in the rat brain[3].
Animal Model: | Adult male Wistar rats (150-175 g)[3] | Dosage: | 5 mg/kg | Administration: | Intraperitoneal injection, daily for 4 or 10 weeks | Result: | Induced a very significant reduction (more than 50%) of serotonin (S2) receptor density after 4 weeks or 10 weeks of daily injection, but did not produce any significant increase in dopamine receptor density. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 100 mg/mL(224.27 mM;Need ultrasonic) H2O : 2.5 mg/mL(5.61 mM;ultrasonic and warming and heat to 60℃) 配制储备液 1 mM | 2.2427 mL | 11.2133 mL | 22.4266 mL | 5 mM | 0.4485 mL | 2.2427 mL | 4.4853 mL | 10 mM | 0.2243 mL | 1.1213 mL | 2.2427 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.61 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.61 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.61 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.61 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.61 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.61 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|